Diabetes is accompanied by a thrombosis-prone status [1,2]. Available evidence shows that an activation of the thrombosis may be generated by hyperglycemia [1,2]. A pro-thrombotic status may be induced by hyperglycemia through two different pathways: oxidative stress and non-enzymatic glycation [1,2]. Acute hyperglycemia, through oxidative stress, increases thrombin generation [3], while the non-enzymatic glycation reduces the functionality of both antithrombin III and heparin co-factor II [4,5]. In conclusion, evidence shows that hyperglycemia may produce a pro-thrombotic status, due to an imbalance between pro-coagulation, anti-coagulation and fibrinolysis [1,2,6].
Mishra et al. have recently reported in the case of COVID-19 an increase of D-dimer in people with diabetes compared to people without diabetes [7]. Evidence is showing that high blood glucose can condition the prognosis of COVID-19 [8,9]. Interestingly, in people with hyperglycemia and COVID-19 increased D-dimer levels have been found [8,9]. Moreover, it has been shown that reducing hyperglycemia is followed by a decrease of the D-dimer [9]. This evidence suggests that hyperglycemia might favor the generation of the thrombosis, a complication very often is present in the COVID-19 [10,11].
If confirmed in specific well-designed studies, this hypothesis may pay the way to possible useful interventions. A fast reduction of hyperglycemia, for its important implications on coagulation activation [1,2], might be very important, while non-enzymatic glycation is, at the beginning, a reversible phenomenon [12]. Furthermore, a fast use of heparin may also be very relevant and not only for its obvious anticoagulant property: heparin can spare antithrombin III and heparin co-factor II from being glycated [4,5].
In conclusion, because thrombosis affects the prognosis of people with COVID-19 [13], understanding what contributes to increase the risk for a thrombotic event in this disease is highly relevant. Therefore, clarifying the possible link between hyperglycemia and thrombosis with specific studies might be very useful for a better management of COVID-19.
Funding
None.
AC wrote, revised and approved the final version of the manuscript.
Declaration of competing interest
Antonio Ceriello does not have conflicts of interest to declare.
References
- 1.Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia. 1993;36:1119–1125. doi: 10.1007/BF00401055. [DOI] [PubMed] [Google Scholar]
- 2.Lemkes B.A., Hermanides J., Devries J.H., Holleman F., Meijers J.J.C.M., Hoekstra B.L. Hyperglycemia: a prothrombotic factor? J Thromb Haemostasis. 2010;8:1663–1669. doi: 10.1111/j.1538-7836.2010.03910.x. [DOI] [PubMed] [Google Scholar]
- 3.Ceriello A., Giacomello R., Stel G., Motz E., Taboga C., Tonutti L. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes. 1995;44:924–928. doi: 10.2337/diab.44.8.924. [DOI] [PubMed] [Google Scholar]
- 4.Ceriello A., Giugliano D., Quatraro A., Consoli G., Stante A., Dello Russo P. Induced hyperglycemia alters antithrombin III activity but not its plasma concentration in healthy normal subjects. Diabetes. 1987;36:320–323. doi: 10.2337/diab.36.3.320. [DOI] [PubMed] [Google Scholar]
- 5.Ceriello A., Marchi E., Barbanti M., Milani M.R., Giugliano D., Quatraro A. Non-enzymatic glycation reduces heparin cofactor II anti-thrombin activity. Diabetologia. 1990;33:205–207. doi: 10.1007/BF00404797. [DOI] [PubMed] [Google Scholar]
- 6.Ceriello A., Quatraro A., Marchi E., Barbanti M., Giugliano D. Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide. Diabete Metab. 1993;19:225–229. [PubMed] [Google Scholar]
- 7.Mishra Y., Pathak B.K., Mohakuda S.S., Tilak T.V.S., Sen S., Harikrishnan P. Relation of D-dimer levels of COVID-19 patients with diabetes mellitus. Diabetes Metab Syndr. 2020;14:1927–1930. doi: 10.1016/j.dsx.2020.09.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zhu L., She Z.G., Cheng X., Qin J.J., Zhang X.J., Cai J. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metabol. 2020;31:1068–1077. doi: 10.1016/j.cmet.2020.04.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Sardu C., D’Onofrio N., Balestrieri M.L., Barbieri M., Rizzo M.R., Messina V. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care. 2020;43:1408–1415. doi: 10.2337/dc20-0723. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Ceriello A., De Nigris V., Prattichizzo F. Why is hyperglycaemia worsening COVID-19 and its prognosis? Diabetes Obes Metabol. 2020 doi: 10.1111/dom.14098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ceriello A., Standl E., Catrinoiu D., Itzhak B., Lalic N.M., Rahelic D. Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. Issues of cardiovascular risk management in people with diabetes in the COVID-19 era. Diabetes Care. 2020;43:1427–1432. doi: 10.2337/dc20-0941. [DOI] [PubMed] [Google Scholar]
- 12.Ceriello A., Paolisso G., Dello Russo P., Giugliano D., Sgambato S. Influence of labile glucose adducts on glycosylated protein assay by aminophenylboronic acid affinity chromatography: in vivo studies. Acta Diabetol Lat. 1985;22:81–82. doi: 10.1007/BF02591096. [DOI] [PubMed] [Google Scholar]
- 13.Cattaneo M., Bertinato E.M., Birocchi S., Brizio C., Malavolta D., Manzoni M. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemostasis. 2020;120:1230–1232. doi: 10.1055/s-0040-1712097. [DOI] [PMC free article] [PubMed] [Google Scholar]